Patents by Inventor Weijia Ou

Weijia Ou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210170043
    Abstract: Provided herein are immunoconjugates comprising an anti-DC-SIGN antibody conjugated to a STING agonist. Also disclosed are methods of making the immunoconjugates and methods of treating cancer using the immunoconjugates.
    Type: Application
    Filed: October 30, 2019
    Publication date: June 10, 2021
    Inventors: Lisa BARNETT, Steven BENDER, Charles Y. CHO, Sarah COX, Jonathan Deane, Scott Martin GLASER, Xueshi Hao, Shailaja KASIBHATLA, Weijia OU, Tetsuo UNO, Yongqin WAN, Ben WEN, Tom Yao-Hsiang WU
  • Publication number: 20200405875
    Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Application
    Filed: June 4, 2020
    Publication date: December 31, 2020
    Inventors: Tinya ABRAMS, Steven Bruce COHEN, Dylan DANIEL, Catrin FINNER, Bernhard Hubert GEIERSTANGER, Thomas HUBER, William Mallet, Matthew John MEYER, Weijia OU, Siew Ho SCHLEYER, Kathrin Ulrike TISSOT-DAGUETTE
  • Publication number: 20200338207
    Abstract: The present invention provides specific sites for modifying antibodies or antibody fragments by replacing at least one native amino acid in the constant region of a parental antibody or antibody fragment with cysteine, which can be used as a site of attachment for a payload or linker-payload combination.
    Type: Application
    Filed: December 3, 2019
    Publication date: October 29, 2020
    Applicant: NOVARTIS AG
    Inventors: Bernhard Hubert Geierstanger, Weijia Ou, Tetsuo Uno
  • Patent number: 10787480
    Abstract: Disclosed herein are novel cytotoxic peptides of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel cytotoxic peptide linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.
    Type: Grant
    Filed: June 12, 2019
    Date of Patent: September 29, 2020
    Assignee: Novartis AG
    Inventors: Bernhard Hubert Geierstanger, Jan Grunewald, Yunho Jin, Weijia Ou, Tetsuo Uno, Yongqin Wan, Xing Wang
  • Patent number: 10786578
    Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Grant
    Filed: July 27, 2015
    Date of Patent: September 29, 2020
    Assignee: Novartis AG
    Inventors: Tinya Abrams, Steven Bruce Cohen, Dylan Daniel, Catrin Finner, Bernhard Hubert Geierstanger, Thomas Huber, William Mallet, Matthew John Meyer, Weijia Ou, Siew Ho Schleyer, Kathrin Ulrike Tissot-Daguette
  • Publication number: 20190382441
    Abstract: Disclosed herein are novel cytotoxic peptides of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel cytotoxic peptide linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.
    Type: Application
    Filed: June 12, 2019
    Publication date: December 19, 2019
    Inventors: Bernhard Hubert GEIERSTANGER, Jan GRUNEWALD, Yunho JIN, Weijia OU, Tetsuo UNO, Yongqin WAN, Xing WANG
  • Patent number: 10392421
    Abstract: Disclosed herein are novel cytotoxic peptides of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel cytotoxic peptide linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.
    Type: Grant
    Filed: April 24, 2018
    Date of Patent: August 27, 2019
    Assignee: Novartis AG
    Inventors: Bernhard Hubert Geierstanger, Jan Grunewald, Yunho Jin, Weijia Ou, Tetsuo Uno, Yongqin Wan, Xing Wang
  • Publication number: 20190194315
    Abstract: This application discloses anti-P-cadherin antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments, particularly antibody drug conjugates comprising anti-P-cadherin antibodies conjugated to auristatin analogs. The invention also relates to methods of treating cancer using the antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.
    Type: Application
    Filed: June 17, 2016
    Publication date: June 27, 2019
    Applicant: Novartis AG
    Inventors: Tinya ABRAMS, Steven Bruce COHEN, Joseph Anthony D'Alessio, Jason Damiano, Clemens Durr, Bernhard Hubert GEIERSTANGER, Qi-Ying HU, Thomas HUBER, Hidetomo IMASE, Yunho JIN, Daniel MENEZES, Kathy MILLER, Morvarid MOHSENI, Weijia OU, Katherine RENDAHL, Tetsuo UNO, Yongqin WAN, Xing WANG
  • Patent number: 10280139
    Abstract: Disclosed herein are novel compounds of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel compound linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: May 7, 2019
    Assignee: Novartis AG
    Inventors: Bernhard Hubert Geierstanger, Jan Grunewald, Weijia Ou, Shifeng Pan, Tetsuo Uno, Yongqin Wan, Xing Wang
  • Publication number: 20180244717
    Abstract: Disclosed herein are novel cytotoxic peptides of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel cytotoxic peptide linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.
    Type: Application
    Filed: April 24, 2018
    Publication date: August 30, 2018
    Inventors: Bernhard Hubert GEIERSTANGER, Jan GRUNEWALD, Yunho JIN, Weijia OU, Tetsuo UNO, Yongqin WAN, Xing WANG
  • Publication number: 20180193475
    Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Application
    Filed: July 27, 2015
    Publication date: July 12, 2018
    Inventors: Tinya ABRAMS, Steven Bruce COHEN, Dylan DANIEL, Catrin FINNER, Bernhard Hubert GEIERSTANGER, Thomas HUBER, William MALLET, Matthew John MEYER, Weijia OU, Siew Ho SCHLEYER, Kathrin Ulrike TISSOT-DAGUETTE
  • Publication number: 20180155281
    Abstract: Disclosed herein are novel compounds of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel compound linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.
    Type: Application
    Filed: November 27, 2017
    Publication date: June 7, 2018
    Inventors: Bernhard Hubert Geierstanger, Jan Grunewald, Weijia OU, Shifeng Pan, Tetsuo Uno, Yongqin Wan, Xing Wang
  • Patent number: 9988420
    Abstract: Disclosed herein are novel cytotoxic peptides of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel cytotoxic peptide linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: June 5, 2018
    Assignee: Novartis AG
    Inventors: Bernhard Hubert Geierstanger, Jan Grunewald, Weijia Ou, Tetsuo Uno, Yongqin Wan, Xing Wang, Yunho Jin
  • Patent number: 9938323
    Abstract: The invention disclosed herein relates to cytotoxic cyclic peptides of Formula (I), methods of inhibiting RNA polymerase with such cyclic peptides, immunoconjugates comprising such cyclic peptides (i.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: April 10, 2018
    Assignee: Novartis AG
    Inventors: Jan Grunewald, Yunho Jin, Weijia Ou, Tetsuo Uno
  • Patent number: 9884817
    Abstract: Disclosed herein are novel compounds of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel compound linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: February 6, 2018
    Assignee: Novartis AG
    Inventors: Bernhard Hubert Geierstanger, Jan Grunewald, Weijia Ou, Shifeng Pan, Tetsuo Uno, Yongqin Wan, Xing Wang
  • Publication number: 20170355731
    Abstract: The invention disclosed herein relates to cytotoxic cyclic peptides of Formula (I), methods of inhibiting RNA polymerase with such cyclic peptides, immunoconjugates comprising such cyclic peptides (i.
    Type: Application
    Filed: November 5, 2015
    Publication date: December 14, 2017
    Inventors: Jan Grunewald, Yunho Jin, Weijia Ou, Tetsuo Uno
  • Publication number: 20170121282
    Abstract: Disclosed herein are novel compounds of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel compound linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.
    Type: Application
    Filed: June 11, 2015
    Publication date: May 4, 2017
    Applicant: NOVARTIS AG
    Inventors: Bernhard Hubert Geierstanger, Jan Grunewald, Weijia OU, Shifeng Pan, Tetsuo Uno, Yongqin Wan, Xing Wang
  • Patent number: 9624520
    Abstract: Disclosed herein is pyrroline-carboxy-lysine (PCL), a pyrrolysine analog, which is a natural, biosynthetically generated amino acid, and methods for biosynthetically generating PCL. Also disclosed herein are proteins, polypeptides and peptides that have PCL incorporated therein and methods for incorporating PCL into such proteins, polypeptides and peptides. Also disclosed herein is the site-specific derivatization of proteins, polypeptides and peptides having PCL or pyrrolysine incorporated therein. Also disclosed herein is the crosslinking of proteins, polypeptides and peptides having PCL or pyrrolysine incorporated therein.
    Type: Grant
    Filed: May 15, 2014
    Date of Patent: April 18, 2017
    Assignee: Novartis AG
    Inventors: Bernhard Geierstanger, Weijia Ou, Susan E. Cellitti, Tetsuo Uno, Tiffany Crossgrove, Hsien-Po Chiu, Jan Grunewald, Xueshi Hao
  • Publication number: 20170021033
    Abstract: The present application provides specific sites for modifying antibodies or antibody fragments by replacing at least one native amino acid in the constant region of a parental antibody or antibody fragment with cysteine, which can be used as a site of attachment for a payload or linker-payload combination. In one embodiment, the antibodies are modified with cysteines at positions 152 and 375 of the heavy chain constant region, as defined by EU numbering format. In another embodiment, the antibodies are modified with cysteines at position 360 of the heavy chain constant region, and position 107 of the kappa light chain constant region, as defined by EU numbering format.
    Type: Application
    Filed: March 11, 2015
    Publication date: January 26, 2017
    Applicant: NOVARTIS AG
    Inventors: Bernhard Hubert GEIERSTANGER, Weijia OU
  • Publication number: 20160311853
    Abstract: Disclosed herein are novel cytotoxic peptides of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel cytotoxic peptide linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.
    Type: Application
    Filed: December 17, 2014
    Publication date: October 27, 2016
    Applicant: NOVARTIS AG
    Inventors: Bernhard Hubert GEIERSTANGER, Jan GRUNEWALD, Weijia OU, Tetsuo UNO, Yongqin WAN, Xing WANG, Yunho JIN